Third Arc Bio: Funding, Investors & Team (Oct 2026)
Third Arc Bio is a biotechnology company that is working on the creation of versatile antibodies for diseases related to inflammation and immunology. The company's drug development process focuses on producing top-quality biologics that enhance T-cell activation by using two cutting-edge technologies. These technologies, the solid tumor synergy platform and the I&I platform, are utilized to develop a range of valuable therapeutic products. The I&I platform specifically aims to provide a unique method of precision immune regulation at a tissue-specific level in order to achieve better effectiveness and safety.
Third Arc Bio has raised $217M across 2 funding rounds on record, the most recent a Series A of $52.0M announced in Feb 2026.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Third Arc Bio Company Profile and Key Stats
Latest funding round on record: Feb 2026.
Third Arc Bio Funding Rounds
Third Arc Bio raised $165M in a Series A announced in Jul 2024.
1.6 years later, a Series A of $52.0M was announced in Feb 2026.
Third Arc Bio Founders and Leadership Team
Contact details for the Third Arc Bio team: 1 of 1 has an email address on file.
Start 14-day free trial →Third Arc Bio Funding Compared to Other Biotechnology Startups
Third Arc Bio's latest round of $52.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Third Arc Bio in Biotechnology and Boston
Companies Similar to Third Arc Bio
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Third Arc Bio Funding FAQs
What does Third Arc Bio do?
Third Arc Bio is a biotechnology company that is working on the creation of versatile antibodies for diseases related to inflammation and immunology. The company's drug development process focuses on producing top-quality biologics that enhance T-cell activation by using two cutting-edge technologies. These technologies, the solid tumor synergy platform and the I&I platform, are utilized to develop a range of valuable therapeutic products. The I&I platform specifically aims to provide a unique method of precision immune regulation at a tissue-specific level in order to achieve better effectiveness and safety.
How much funding has Third Arc Bio raised?
Third Arc Bio has raised $217M across 2 rounds on record. The most recent is a Series A of $52.0M announced in Feb 2026.
When did Third Arc Bio last raise funding?
Third Arc Bio's most recent funding round on record is a Series A of $52.0M, announced in Feb 2026.
Who founded Third Arc Bio?
FundedIQ lists Sanjaya Singh (Founder) at Third Arc Bio.
Where is Third Arc Bio headquartered?
Third Arc Bio is based in Boston, Massachusetts, United States.
How many employees does Third Arc Bio have?
Third Arc Bio is in the 1-10 employee band.
How does Third Arc Bio's funding compare to other Biotechnology startups?
Third Arc Bio's latest round of $52.0M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Third Arc Bio Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Third Arc Bio is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.